购物车
- 全部删除
- 您的购物车当前为空
hCAIX/XII-IN-13是一种针对人类碳酸酐酶 (hCA) IX和XII亚型的抑制剂,展现出高效的抑制效果,其Ki值分别达到0.08 µM 和 0.06 µM。此外,hCAIX/XII-IN-13能在缺氧条件下增强Doxorubicin对MCF-7细胞的细胞毒作用,通过促进G2/M期的细胞周期阻滞和细胞凋亡 (apoptosis) 来发挥作用。
hCAIX/XII-IN-13是一种针对人类碳酸酐酶 (hCA) IX和XII亚型的抑制剂,展现出高效的抑制效果,其Ki值分别达到0.08 µM 和 0.06 µM。此外,hCAIX/XII-IN-13能在缺氧条件下增强Doxorubicin对MCF-7细胞的细胞毒作用,通过促进G2/M期的细胞周期阻滞和细胞凋亡 (apoptosis) 来发挥作用。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | hCAIX/XII-IN-13 functions as an inhibitor targeting specific human carbonic anhydrases (hCA) IX and XII, crucial in tumor-related processes. Demonstrating efficacy, this compound offers inhibitory K i values of 0.08 µM for IX and 0.06 µM for XII. Additionally, under hypoxic conditions, hCAIX/XII-IN-13 enhances the effectiveness of Doxorubicin on MCF-7 cells by promoting G2/M phase cell cycle arrest and increasing apoptosis. |
分子量 | 528.50 |
分子式 | C25H16N6O6S |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.